This satellite symposium will cover key considerations for incorporating WG(T)S into the workup of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and other hematologic malignancies. It will feature speakers from industry, academic medical centers and community health systems that have or are in the process of implementing clinical WG(T)S for AML, MDS, and other blood cancers and leverage their expertise to drive important conversations about the current and future clinical utility of WG(T)S in hematologic malignancies. Speakers will provide short presentations covering a variety of topics including, the rationale and benefits of WG(T)S for hematological malignancies, comparison to standard of care testing modalities, workflow and bioinformatic solutions, clinical utilization and ongoing studies at their institutes, and future directions. This workshop will conclude with a question-and-answer session with all speakers to address audience questions.